Fabio Paio

Fabio Paio

Auto-generated profile, based on publicly available information

Fabio Paio

Neurology Unit, Department of Neurosciences, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 December 2024 in Neurological Sciences
Verified
Journal Article
Closed access
PDF file
GRGiuseppe Kenneth Ricciardi
Giuseppe Kenneth Ricciardi
FPFabio Paio
Fabio Paio
CZCecilia Zivelonghi
Cecilia Zivelonghi
Michele LonghiMichele Longhi
Michele Longhi
GBGiorgia Bulgarelli
Giorgia Bulgarelli
Stefano TamburinStefano Tamburin
Stefano Tamburin

31 March 2026 in European Journal of Neurology
Verified
Journal Article
Open access
FPF. Paio
F. Paio
GRG. K. Ricciardi
G. K. Ricciardi
GBG. Bulgarelli
G. Bulgarelli
MTM. Tagliamonte
M. Tagliamonte
EMElisa Mantovani
Elisa Mantovani
Stefano TamburinStefano Tamburin
Stefano Tamburin
Background: Staged bilateral Magnetic Resonance–guided Focused Ultrasound (MRgFUS) thalamotomy is an incisionless option for medication‐refractory essential tremor (ET). While the efficacy and safety of unilateral MRgFUS are established, evidence for bilateral treatment remains limited. Objective: To evaluate the efficacy and safety of staged bilateral MRgFUS in a prospective single‐centre observational cohort and to perform a systematic review and meta‐analysis of the literature. Methods: Consecutive ET patients undergoing second‐side MRgFUS were prospectively assessed. The primary efficacy endpoint was the longitudinal change in Clinical Rating Scale for Tremor (CRST) A + B scores for the treated hand after FUS2, while safety was evaluated by collecting and grading adverse events (AEs). A systematic review identified published bilateral MRgFUS series; efficacy data were meta‐analysed, while AEs were reported descriptively. Results: Fifteen patients (60% men; mean age 74.1 ± 8.9 years) underwent FUS2 28.9 ± 22.5 months after first‐side treatment. At the 12‐month evaluation, CRST A + B decreased from 21.0 to 8.8 (−58%), CRST C from 7.3 to 1.9 (−74.2%), and QUEST from 30.5 to 9.5 (−68.7%). Head and voice tremor were reduced by 73.8% and 40.3%, respectively. AEs were predominantly mild (95.2%) and transient (88%). Cognition at 1 year was globally preserved, with a selective decline in verbal episodic memory. Meta‐analysis confirmed significant improvement in tremor severity. Conclusion: Staged bilateral MRgFUS thalamotomy was associated with sustained tremor reduction, including midline tremor, functional improvement and acceptability, with a manageable safety profile. Overall, consistent with literature, these findings support its potential role as a therapeutic option in selected ET patients.

30 April 2026 in Journal of Neurology
Verified
Journal Article
Open access
Marialuisa GandolfiMarialuisa Gandolfi
Marialuisa Gandolfi
ASAngela Sandri
Angela Sandri
MRMichela Russo
Michela Russo
ESElisabetta Sarasso
Elisabetta Sarasso
AGAndrea Gardoni
Andrea Gardoni
MTMichele Tinazzi
Michele Tinazzi
Functional motor disorders (FMDs) represent a frequent and disabling neurological condition. The lack of reliable diagnostic biomarkers and their heterogeneity might affect diagnosis. We identified multimodal biomarkers distinguishing FMDs from healthy controls (HCs) using machine-learning approaches. In this multicenter cross-sectional study, consecutive adults with a clinically established FMDs diagnosis (n = 75, 74.7% female; mean age 44.20 ± 12.92) and age- and sex-matched HCs (n = 75; 58.6% female; 48.42 ± 11.67) were recruited. All participants underwent standardized behavioral, neurophysiological, and brain MRI assessment exploring motor, exteroceptive, and interoceptive domains. A Random Forest (RF) classifier combined with repeated stratified k-fold cross-validation was trained on the collected features. Predictive performance was evaluated using accuracy, sensitivity, specificity, precision, F1-score, and AUC-ROC. SHapley Additive exPlanations interpreted feature importance. The strongest diagnostic biomarkers were lower dual-task effect scores for postural sway area under eyes-closed motor and cognitive conditions, and gait speed during the motor dual-task, followed by increased vDMN and basal ganglia networks functional connectivity, reduced baseline ipsilateral-contralateral R2 blink reflex area, and higher DNIC-to-baseline N2P2 amplitude ratios for the lower limb. The RF classifier achieved robust performance (accuracy 85.0%, sensitivity 83.9%, specificity 86.1%, F1-score 85.7%, AUC-ROC 0.921). Motor, functional neuroimaging, and neurophysiological markers demonstrated diagnostic value in distinguishing FMDs from healthy controls, addressing the current lack of objective tools and supporting more confident and accurate diagnosis of these heterogeneous conditions. Trial registration number NCT06328790. Registered on 26 March 2024.

2 January 2026 in Clinical Neurophysiology
Verified
Journal Article
Closed access
Giovanna SquintaniGiovanna Squintani
Giovanna Squintani
MMMarta Di Muzio
Marta Di Muzio
ARAndrea Rasera
Andrea Rasera
FPFabio Paio
Fabio Paio
GBGiovanni Umberto Borin
Giovanni Umberto Borin
MEMario Ermani
Mario Ermani

12 November 2025 in Movement Disorders
Verified
Journal Article
Open access
RERoberto Eleopra
Roberto Eleopra
FPFabio Paio
Fabio Paio
SRSara Rinaldo
Sara Rinaldo
CCCarla Carozzi
Carla Carozzi
AOAmanda Oriana
Amanda Oriana
VLValentina Leta
Valentina Leta
Background: Functional dystonia ( FD ) is one of the most diagnostically challenging functional movement disorders. Phenomenological features often lack specificity, as many are also observed in idiopathic dystonia ( ID ) and validated biomarkers to distinguish FD from ID are currently unavailable Objective: To investigate potential differences in muscle activity between ID and FD patients using polyelectromyography (PEMG) under anesthesia. Methods: We consecutively enrolled 10 patients with FD and 17 with ID according to the current diagnostic criteria who underwent continuous PEMG before, during, and after propofol infusion. Sedation levels were monitored by electroencephalography and bispectral index and stratified via the Observer's Assessment of Alertness/Sedation Scale (OASS). PEMG recordings were performed under five definite scenarios: alert, mild and deep sedation, and partial and full recovery of consciousness status. Presence/absence of EMG activity was evaluated across these stages, and changes from baseline patterns were analyzed. Results: During mild sedation, EMG activity persisted in all ID (100%) and in 9 (90%) FD patients. During deep sedation, EMG activity persisted in 9 (53%) ID patients and was absent in all FD patients (100%) ( P = 0.01). During partial recovery of consciousness, EMG activity was present in all (100%) ID and only in 1 (10%) FD patients ( P < 0.001). At full recovery, a different muscular activation pattern from baseline was observed in 7 (70%) FD and only in 1 (6%) ID patients ( P = 0.001) Conclusions: EMG silence during deep sedation and partial recovery may serve as a neurophysiological marker of FD . A muscular activation pattern differing from baseline may represent a neurophysiological clue for incongruence © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

13 March 2026 in Parkinsonism & Related Disorders
Verified
Journal Article
Open access
FPFabio Paio
Fabio Paio
GBGiorgia Bulgarelli
Giorgia Bulgarelli
MTMicaela Tagliamonte
Micaela Tagliamonte
TBTommaso Bovi
Tommaso Bovi
MLMichele Longhi
Michele Longhi
STStefano Tamburin
Stefano Tamburin
Magnetic resonance-guided focused ultrasound (MRgFUS) is an established incisionless treatment for essential tremor (ET), Parkinson's disease (PD) and neuropathic pain. Although efficacy and safety are supported by randomised trials and large series, peri-procedural management remains non-standardised. We conducted a structured, web-based survey of 41 centres performing MRgFUS for neurological indications across Europe, Middle East, and Africa (EMEA) region. The 35-item questionnaire covered four domains: centre activity and indications, discharge policy and reimbursement, use of corticosteroids and other medications, and team composition. Responses were anonymised and analysed descriptively. Twenty-seven respondents (28 MRgFUS centres, 68% coverage) answered the questionnaire. Caseloads varied widely, from 400 cumulative procedures, with ET treated in all centres and PD in 70%. Discharge practice ranged from same-day to >48-h admission, and reimbursement was by national health system in 77.8%, mixed in 7.4%, and borne by patient/insurance in 14.8% of centres. Corticosteroids were used routinely in 63.0% of centres, selectively in 29.6%, and never in 7.4%, with marked heterogeneity in timing and tapering. Analgesics and antiemetics were routinely prescribed in 66.7% and 70.4% of centres, respectively. Sedatives or anaesthetic agents were rarely used, mirroring variability in anaesthesiologist involvement. A dedicated nurse in the MRI suite was reported by 63.0% of centres. Peri-procedural MRgFUS management is highly heterogeneous across EMEA centres, particularly regarding corticosteroid protocols and anaesthesiologist support. Future consensus work and prospective, registry-based studies will address these issues and define evidence-based, harmonised care pathways.